Cwestiwn ysgrifenedig WQ97588
- Gofynnwyd gan
- Mark IsherwoodCeidwadwyr
- I'w ateb gan
- Cabinet Secretary for Health and Social Care
- Cyflwynwyd
- Dyddiad ateb
- Atebwyd
- Amser i'w ateb
- 5 diwrnod
Cwestiwn
Mae'r cwestiwn a'r ateb yn Saesneg gan nad oes fersiwn Gymraeg ar gael.
Further to WQ96965, will the Cabinet Secretary provide an update on the availability of Alyftrek for treatment of cystic fibrosis on the NHS?
Ateb
Atebwyd gan Cabinet Secretary for Health and Social Care
The NHS Wales Shared Services Partnership’s Medicines’ Value Unit is working closely with the manufacturer to finalise the commercial agreement for Alyftrek®. The commercial agreement covering Alyftrek® is particularly complex and forms part of a wider agreement covering other medicines for cystic fibrosis; Kaftrio®, Kalydeco®, Symveki® and Orkambi®.
Whilst NHS Wales was ready to negotiate the agreement at the point at which NICE made its recommendation, the manufacturer decided to conclude its agreement with NHS England before starting discussions with the NHS in Wales. This has led to a short delay in making Alyftrek® available.
I am assured the agreement will be completed shortly, making Alyftrek® the latest in the line of life changing treatments for Cystic Fibrosis routinely available for patients in Wales.